- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04452409
Enhanced Liver Function in Non-alcoholic Obese Fatty Liver Patients by Low Level Laser Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Non-alcoholic fatty liver disease (NAFLD) is a very common disorder and refers to a group of conditions where there is accumulation of excess fat in the liver of people who drink little or no alcohol. The most common form of NAFLD is a non serious condition called fatty liver.
NAFLD is part of the metabolic syndrome characterized by diabetes, or pre-diabetes (insulin resistance), being overweight or obese, elevated blood lipids such as cholesterol and triglycerides, as well as high blood pressure. A few studies have suggested that weight loss may be associated with regression of fat within the liver. Therefore, the most important recommendations for people with fatty liver are to lose weight if they are overweight or obese, increase their physical activity, follow a balanced diet and unnecessary medications.
Several studies have investigated low-level laser therapy (LLLT) or light-emitting diode (LED) therapy and have made advances in the understanding of the underlying mechanisms LLLT in biological systems. Few studies explain the effect of low level laser therapy on liver enzymes and non alcoholic fatty liver risk factors (as obesity).So, our goal was to perform a randomized controlled trial to investigate the effects of the LLLT on lipid profile, body weight and liver enzymes
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Dokki
-
Giza, Dokki, Egypt, 11432
- Cairo
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
• Sixty non-alcoholic fatty liver patients aged from 60-75 y
- Body mass index (BMI) ranged from 30 to 34.9 kg/m2
- Elevated triglyceride & LDL levels
- Higher Risk Waist Circumference Measurements (Men: 40 or more inches or 102 centimeters or more/ Women: 35 or more inches or 89 centimeters or more)
- Elevated aminoalanine transaminase (ALT) level, defined as 20 or more Unites/Liter (U/L) above the normal gender-specific ALT levels: males: ALT ≥ 60 U/L; females: ALT ≥ 50 U/L
- Review of subject's pre-existing medical records to confirm the current diagnosis of nonalcoholic fatty liver according to the following criteria:
- ALT elevated on two separate determinations
- Abdominal ultrasound showing fatty liver
- Blood work that excludes other potential etiologies of liver disease
- Subject agrees to maintain his or her diet regimen throughout study participation
Exclusion Criteria:
• History of cardiovascular disease or events including, but not limited to, coronary artery disease, valvular heart disease, cardiac arrhythmias, congestive heart failure, myocardial infarction, stroke, transient ischemic attack, or peripheral vascular disease
- Cardiac surgeries or procedures, including but not limited to, coronary artery bypass surgery or stent placement, heart transplantation, pacemaker insertion or implantation of a defibrillator
- An implanted device in the target area to receive low level laser light therapy (e.g. pain pump, lap band, penile inflation device, ventriculo-peritoneal shunts, etc.)
- Known photosensitivity disorder
- Current active cancer or within one year of cancer treatment or remission
- Excessive alcohol consumption defined as 14 or more alcoholic drinks per week
- Serious mental health illness that in the opinion of the investigator would preclude the subject from study participation
- Active infection, wound or other external trauma to the target area to receive the laser therapy
- Developmental disability or cognitive impairment that in the opinion of the investigator would preclude adequate comprehension of the informed consent form and/or ability to record the necessary study measurements
- Participation in a clinical study or other type of research in the past 30 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: study (low level laser plus Mediterranean diet)
Active infra -red laser in addition to diet
|
The laser therapy device (660 nm) consisted of abdominal straps containing 4 LED clusters, having 72 LEDs each, applied in the study group paticipants around the patients abdomen and waist after cleaning the target area and wearing safety goggles20, for 30 min., 2 times per week over 12 weeks
recommend healthy diet component evaluated periodically by 24 hour recall
|
Other: control (Mediterranean diet only)
diet
|
recommend healthy diet component evaluated periodically by 24 hour recall
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
changes in liver function
Time Frame: 3 months
|
measuring liver enzymes (alanine transaminase (ALT) & aspartate aminotransferase (AST) ) and alkaline phosphate before and after low level laser application and the prescribed diet recommendations
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
changes of lipid profile
Time Frame: 3 months
|
measuring effect of low level laser application in addition to diet recommendations on lipid profile (low density lipoprotein LDL, high density lipoprotein HDL, total cholesterol T.C and triglyceride T.G)
|
3 months
|
changes of Body Mass Index
Time Frame: 3 months
|
measuring effect of low level laser application in addition to diet recommendations on body mass index (weight by Kg / height per meter square)
|
3 months
|
changes of waist circumference
Time Frame: 3 months
|
measuring effect of low level laser application in addition to diet recommendations on waist circumference
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ebtesam Nabil, doctoral, Cairo University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P.T.REC/012/002722
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Supporting Information Type
- Study Protocol
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fatty Liver, Nonalcoholic
-
Merck Sharp & Dohme LLCRecruitingNon-alcoholic Fatty Liver Disease | NAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis | Fatty Liver, NonalcoholicCanada, United States, Puerto Rico, Israel, Japan, Korea, Republic of, Taiwan, Spain, Chile, France, Italy, Hungary, Switzerland, Belgium, China, Singapore, Czechia, Portugal, Austria, United Kingdom, Thailand, Hong Kong, Turkey
-
Columbia UniversityThorne Research Inc.WithdrawnNASH - Nonalcoholic Steatohepatitis | NAFLD - Nonalcoholic Fatty Liver Disease
-
University of AarhusCompletedNASH - Nonalcoholic Steatohepatitis | NAFLD - Nonalcoholic Fatty Liver DiseaseDenmark
-
Columbia UniversityPfizerWithdrawnNASH (Nonalcoholic Steatohepatitis) | NAFLD (Nonalcoholic Fatty Liver Disease)
-
AdventHealth Translational Research InstituteCompletedNASH - Nonalcoholic Steatohepatitis; NAFLD - Nonalcoholic Fatty Liver DiseaseUnited States
-
AstraZenecaCompletedNon-alcoholic Fatty Liver Disease | NAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis | NASH | Fatty Liver, NonalcoholicUnited States
-
Duke UniversityCompletedLiver Diseases | Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis | Nonalcoholic Fatty LiverUnited States
-
Shiraz University of Medical SciencesCompletedFatty Liver | Fatty Liver, NonalcoholicIran, Islamic Republic of
-
Gilead SciencesCompletedNonalcoholic Steatohepatitis (NASH) | Nonalcoholic Fatty Liver Disease (NAFLD)United States, New Zealand
-
National Institute of Diabetes and Digestive and...CompletedNonalcoholic Steatohepatitis (NASH) | Nonalcoholic Fatty Liver Disease (NAFLD)United States
Clinical Trials on low level laser
-
University of Texas Southwestern Medical CenterTerminatedChronic PainUnited States
-
Universidade Estadual Paulista Júlio de Mesquita...Completed
-
University of Nove de JulhoSimone Aparecida Penimpedo Calamita; Fabiana Sarilho de Mendonça; Daniela Aparecida... and other collaboratorsCompleted
-
Universidade Federal de Sao CarlosConselho Nacional de Desenvolvimento Científico e TecnológicoCompleted
-
Tehran University of Medical SciencesCompletedGingival RecessionIran, Islamic Republic of
-
University of BergenCompleted
-
University of BergenNorwegian Fund for Postgraduate Training in PhysiotherapyCompleted
-
Legacy Health SystemCompletedPeripheral NeuropathyUnited States
-
St. Elisabethen Krankenhaus Frankfurt GmbHRecruitingSurgical Scar Tissue of Cesarean Section or Vaginal Tear or EpisiotomyGermany
-
Institut Cancerologie de l'OuestUnknownOral Mucositis | Oral Squamous Cell Carcinoma | Squamous Cell Carcinoma of Hypopharynx | Squamous Cell Carcinoma of OropharynxFrance